Citing a lack of participants, the pharmaceutical group of the basel put an end to his trials with hydroxychloroquine to treat the new coronavirus.
The pharmaceutical group of the basel Novartis has put an end to its clinical trial with hydroxychloroquine, to treat diseases induced by the novel coronavirus. It invokes a lack of participants.
The u.s. agency of the drug, the Food and Drug Administration (FDA) had approved the study in April. Some 440 patients infected with the virus and hospitalized were to participate in the testing.
But on Monday, it withdrew its approval for the use of hydroxychloroquine, an anti-malarial drug, explaining that the latest studies confirmed not support the hypothesis of efficacy against pulmonary diseases.
Published today in 02h16